Top

Published in:

01-12-2011 | Original Paper

Significance of epidermal growth factor receptor expression in breast cancer

Authors: Tanja Badovinac-Crnjevic, Jasminka Jakic-Razumovic, Paula Podolski, Stjepko Pleština, Božena Šarčević, Radenka Munjas, Damir Vrbanec

Published in: Medical Oncology | Special Issue 1/2011

Abstract

Recent interest of many investigators is focused on epidermal growth factor receptor (EGFR) family, because of their potential role in the pathogenesis and progression of breast cancer. Paraffin tumor sections were collected retrospectively from 181 breast cancer patients diagnosed between 2002 and 2003. Immunohistochemical staining with ErbB-1, ErbB-2, ErbB-3, and ErbB-4 monoclonal antibodies was performed. The ErbB expression was correlated with the other clinicopathological variables. Overexpression of ErbB-1, ErbB-2, ErbB-3, and ErbB-4 was observed in 20.6, 18.2, 14.3, and 5.7% cases, respectively. Overexpression of ErbB-1 and ErbB-2 was associated with poor prognostic features and decreased 5-year disease-free survival. The patients with co-overexpression of ErbB-1 and ErbB-2 had a shorter DFS, although this difference was not statistically significant. ErbB-1 overexpression may indicate a subset of patients with a poor disease prognosis. Assays for ErbB-1 and ErbB-2 may be more useful than a single assay in predicting prognosis of a breast cancer patient.

Bundred NJ. Prognostic and predictive factors in breast cancer. Cancer Treat Rev. 2001;27:137–42.PubMedCrossRef

Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159–67.PubMedCrossRef

Stern DF. Tyrosine kinase signaling in breast cancer: ErbB family receptor tyrosine kinases. Breast Cancer Res. 2000;2:176–83.PubMedCrossRef

Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82.PubMedCrossRef

Schechter AL, Stern DF, Vaidyanathan L, et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen. Nature. 1984;312:513–6.PubMedCrossRef

Kallioniemi OP, Kallioniemi A, Kurisu W, et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc Natl Acad Sci USA. 1992;89:5321–5.PubMedCrossRef

Moasser MM. The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene. 2007;26:6469–87.PubMedCrossRef

Abd El Rehim DM, Pinder SE, Paish CE, Bell JA, Rampaul SE, Blamey RW, Robertson JFR, Nicholson RI, Ellis IO. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast cancer. Br J Cancer. 2004;91:1532–42.PubMedCrossRef

Sainsbury JR, Farndon JR, Needham GK, et al. Epidermal growth-factor receptor status as predictor of early recurrence of and death from breast cancer. Lancet. 1987;1:1398–402.PubMed

10.

Lewis S, Locker A, Todd JH, et al. Expression of epidermal growth factor receptor in breast carcinoma. J Clin Pathol. 1990;43:385–9.PubMedCrossRef

11.

Toi M, Nakamura T, Mukaida H, Wada T, Osaki A, Yamada H, Toge T, Niimoto M, Hattori T. Relationship between epidermal growth factor receptor status and various prognostic factors in human breast cancer. Cancer. 1990;65:1980–4.PubMedCrossRef

12.

Witton CJ, Reeves JR, Going JJ, Cooke TG, Barlett JMS. Expression of the HER 1–4 family of receptor tyrosine kinases in breast cancer. J Pathol. 2003;200:290–7.PubMedCrossRef

13.

Tsutsui S, Ohno S, Murakami S, Hachitanda Y, Oda S. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patient with breast cancer. Breast Cancer Res Treat. 2002;71:67–75.PubMedCrossRef

14.

Naidu R, Yadav M, Nair S, Kutty MK. Expression of c-erbB3 protein in primary breast carcinoma. Br J Cancer. 1998;78:1385–90.PubMedCrossRef

15.

Travis A, Pinder SE, Robertson JF, et al. C-erbB3 in human breast carcinoma: expression and relation to prognosis and established prognostic indicators. Br J Cancer. 1996;74:229–33.PubMedCrossRef

16.

Kew TY, Bell JA, Pinder SE, Denley H, Srinivasan R, Gullick WJ, Nicholson RI, Blamey RW, Ellis IO. c-ErbB-4 protein expression in human breast cancer. Br J Cancer. 2000;82:1163–70.PubMedCrossRef

17.

Suo Z, Risberg B, Kalsson MG, Willman K, Tierens A, Skovlund E, Nesland JM. EGFR family expression in breast carcinomas. c-ErbB-2 and c-ErbB-4 receptors have different effects on survival. J Pathol. 2002;196:17–25.PubMedCrossRef

18.

Suo Z, Berner HS, Risberg B, Karlsson MG, Nesland JM. Estrogen receptor alpha and C–ERBB–4 expression in breast carcinomas. Vichows Arch. 2001;439:62–9.CrossRef

19.

Knowlden JM, Gee JM, Seery LT, et al. c-erB3 c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer. Oncogene. 1998;17:1949–57.PubMedCrossRef

20.

Lodge AJ, Anderson JJ, Gullick WJ, Haugk B, Leonard RC, Angus B. Type 1 growth factor receptor expression in node positive breast cancer: adverse prognostic significance of c-ErbB-4. J Clin Pathol. 2003;56:300–4.PubMedCrossRef

21.

World Health Organisation. World Health Organisation classification of tumors. Tumors of the breast and female genital organs. In: Tavassoli FA, Devilee P, editors. Lyon: IARC Press; 2003.

22.

Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–10.PubMedCrossRef

23.

Taylor CR. The current role of immunohistochemistry in diagnostic pathology. Adv Pathol Lab Med. 1994;7:59–65.

24.

Key G, Petersen JL, Becker MHG, et al. New antiserum against Ki-67 antigen suitable for double immunostaining of paraffin wax sections. J Clin Pathol. 1993;46:1080–4.PubMedCrossRef

25.

Bartlett JMS, Going JJ, Mallon EA, et al. Evaluating HER2 amplification and overexpression in breast cancer. J Pathol. 2001;195:422–8.PubMedCrossRef

26.

Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat. 1999;53:167–76.PubMedCrossRef

27.

Tsutsui S, Ohno S, Murakami S, et al. Prognostic value of epidermal growth factor receptor (EGFR) and its relationship to the estrogen receptor status in 1029 patients with breast cancer. Breast Cancer Res Treat. 2002;71:67–75.PubMedCrossRef

28.

DiGovanna MP, Stern DF, Edgerotn SM, Whalen SG, Moore D II, Thorn AD. Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients. J Clin Oncol. 2005;23:1152–60.CrossRef

29.

Paik S, Hazan R, Fisher ER, et al. Pathologic findings from the nations’ surgical adjuvant breast and bowel project: prognostic significance of erb B2 protein overexpression in primary breast cancer. J Clin Oncol. 1990;8:103–12.PubMed

30.

Battifora H, Gaffey M, Esteban J, et al. Immunohistochemical assay of neu/c-erb B-2 oncogene product in paraffin-embedded tissues in early breast cancer: Retrospective follow-up study of 245 stage I and II cases. Modern Pathol. 1991;4:466–74.

31.

Lemoine NR, Barnes DM, Hollywood DP, Hughes CM, Smith P, Dublin E, Prigent SA, Gullick WJ, Hurst HC. Expression of the ERBB3 gene product in breast cancer. Br J Cancer. 1992;66:1116–21.PubMedCrossRef

32.

Quinn CM, Ostrowski JL, Lane SA, Loney DP, Teasdale J, Benson FA. C-ErbB-3 protein expression in human beast cancer: comparison with other tumor variables and survival. Histopathology. 1994;25:247–52.PubMedCrossRef

33.

Gasparini G, Gullick WJ, Maluta S, Palma PD, Caffo O, Leonardi E, Borachi P, Pozza F, Lemoine NR. C-erB-3 and C-ErbB-2 protein expression in node negative breast carcinoma—in immunohistochemical study. Eur J Cancer. 1994;30A:16–22.PubMedCrossRef

34.

Junttila TT, Sundvall M, Maatta JA, Elenius K. Erbb4 and its isoforms: selective regulation of growth factor responses by naturally occurring receptor variants. Trends Cardiovasc Med. 2000;10:304–10.PubMedCrossRef

Title: Significance of epidermal growth factor receptor expression in breast cancer
Authors: Tanja Badovinac-Crnjevic
Jasminka Jakic-Razumovic
Paula Podolski
Stjepko Pleština
Božena Šarčević
Radenka Munjas
Damir Vrbanec
Publication date: 01-12-2011
Publisher: Springer US
Published in: Medical Oncology / Issue Special Issue 1/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-010-9738-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Significance of epidermal growth factor receptor expression in breast cancer

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Special Issue 1/2011

Down-regulation of miR-212 expression by DNA hypermethylation in human gastric cancer cells

Inhibition of angiogenic activity of hypoxic fibroblast cell line MRC-5 in vitro by topotecan

Whether drainage should be used after surgery for breast cancer? A systematic review of randomized controlled trials

Potential role of serum level of soluble CD44 and IFN-γ in B-cell chronic lymphocytic leukemia

Inflammatory myofibroblastic tumor of the head and neck

Activity of trabectidin in desmoplastic small round cell tumor

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page